Skip to main content
OpenTrials
Completed

NCT Number: NCT00505817

GnRH Agonist and Antagonists in an Oocyte Donation Program

The primary purpose of this study is to evaluate the effect of the two different protocols (long protocol vs antagonist protocol) on oocyte / embryo quality.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–34 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Instituto Valenciano de Infertilidad Spain

Valencia, 46015, Spain

About this study

The cycles with antagonists of the GnRHa present a series of advantages with respect the GnRHa in an oocyte donation program: treatment cycles are simpler and shorter, a lower amount of dose of gonadotrophins is needed for stimulation, and most important, a decreased rate of ovarian hyperstimulation syndrome is observed. Nevertheless, several clinical trials relate their use to a greater rate of abortion and worse oocyte/ embryo quality. In order to discriminate the endometrial factor from the quality of oocyte cohort, the best strategy is the oocyte donation model. In the present study, for the first time, the effect of different protocols (long versus antagonist protocol) will be studied in the same donor, acting as its own control, undergoing COH. We will compare the COH´s parameters and IVF outcome obtained in the same donor submitted to, firstly, GnRH antagonist protocol (Cetrorelix- n= 45) versus another consecutive cycle with long protocol (Ac. Leuprolide- n= 45).

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • oocyte donors with age range: 18 - 34; BMI: 18 - 29 kg/m2;

Exclusion criteria

  • PCO

Treatment and study plan

Cetrorelix and Leuprolide

Drug

Sponsors and collaborators

Lead sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA

Other

Registry information

Important dates

First posted
Jul 25, 2007
Registry last updated
Jan 12, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.